ScienceChina’s pharma rise: why global drugmakers are buying in
China is emerging as a major force in drug innovation. Chinese companies secured eight of the world’s 10 largest pharmaceutical out-licensing deals in the first half of 2026, worth a record $110 billion, even as the US increases scrutiny of Chinese clinical data. Global drugmakers are betting on China, with AI and traditional medicine part of the race to develop new treatments.
CCGTN★★★☆☆2026-08-12 06:02Original
China’s pharma rise: why global drugmakers are buying in
Science